GenSight Biologics (SIGHT) Q3 2026 TU earnings summary

Executive summary

• Cash and cash equivalents were €0.7 million at September 30, 2026; paid early access programs generated €8.2 million in gross collections since treatments began in March.

• Funding is insufficient for the next 12 months without additional financing or cash inflows; the estimated net funding requirement is €16 million, mainly for RECOVER Phase III preparation and manufacturing.

Financial highlights

• Cash and cash equivalents were €0.7 million at September 30, 2026, versus €1.7 million at June 30, 2026.

• Q3 gross collections from the French named patient early access program were €1.7 million; cumulative gross collections reached €8.2 million from March 2026.

• Collections are reported gross of rebates; the quarterly cash decrease reflected the summer treatment pause, manufacturing technology transfer and RECOVER preparation.

Outlook and guidance

• Treatments through paid early access programs in new countries are expected in Q4 2026.

• With bridge financing of up to €2 million or additional early access cash inflows secured by end-November 2026, available resources are projected to last until late March 2027.

• First significant RECOVER preparation payments are due in late March 2027; without structural financing by then, the trial start would be postponed.